# EDGAR Filing Document

**Accession Number:** 0001479419
**File Stem:** 0001829126-26-000055
**Filing Date:** 2026-1
**Character Count:** 51509
**Document Hash:** b4fe49573c8464afe13de5f95614cac2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-26-000055.hdr.sgml**: 20260106

**ACCESSION NUMBER**: 0001829126-26-000055

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 17

**CONFORMED PERIOD OF REPORT**: 20251230

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260106

**DATE AS OF CHANGE**: 20260106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KALA BIO, Inc.
- **CENTRAL INDEX KEY:** 0001479419
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 270604595
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38150
- **FILM NUMBER:** 26509411

**BUSINESS ADDRESS:**
- **STREET 1:** 1167 MASSACHUSETTS AVENUE
- **CITY:** ARLINGTON
- **STATE:** MA
- **ZIP:** 02476
- **BUSINESS PHONE:** 781-996-5252

**MAIL ADDRESS:**
- **STREET 1:** 1167 MASSACHUSETTS AVENUE
- **CITY:** ARLINGTON
- **STATE:** MA
- **ZIP:** 02476

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Kala Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20091223

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 30, 2025**

**KALA BIO, Inc.**

(Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38150** | **27-0604595** |
| (State or Other Jurisdiction<br> of Incorporation) | (Commission <br> File Number) | (IRS Employer<br> Identification No.) |

---

**1167 Massachusetts Avenue**

**Arlington, MA 02476**

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: **(781) 996-5252**

**Not applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value per share KALA | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 1.01** | **Entry into a Material Definitive Agreement** |

---

On December 30, 2025, KALA BIO, Inc. (the "Company") entered into a settlement agreement with Baker Bros. Advisors LP ("Baker Bros.") under which the Company agreed to issue 900,000 shares of its common stock, par value $0.001 per share ("Common Stock") to resolve certain claims relating to participation rights under prior financing arrangements (the "Baker Settlement"). In connection with the Baker Settlement, the Company and Baker Bros. also entered into a voting agreement (the "Baker Voting Agreement") under which Baker Bros. granted an irrevocable proxy in favor of the Company to vote the settlement shares and other specified shares in line with the Company's board of director's recommendations for a period of six months.

On December 30, 2025, the Company also entered into a settlement agreement with LifeSci Capital LLC ("LifeSci") under which the Company agreed to issue 2,200,000 shares of Common Stock to settle certain payment obligations for financial advisory services (the "LifeSci Settlement").

On December 30, 2025, the Company also entered into a consulting agreement and a settlement agreement with Delaware IR LLC ("Delaware IR"). Under the consulting agreement, Delaware IR agreed to provide marketing and advertising services for a six-month term for $600,000. Under the settlement agreement, the Company agreed to issue 1,100,000 shares of Common Stock to settle the outstanding $600,000 amount owed under the consulting agreement, with a make-whole mechanic tied to ultimate net sale proceeds from the future sales of the 1,100,000 shares of Common Stock (the "Delaware IR Settlement").

The foregoing descriptions of the Baker Settlement, the Baker Voting Agreement, the LifeSci Settlement and the Delaware IR Settlement are not complete and are qualified in their entirety by reference to the full text of each, copies of which are filed as Exhibits 10.1, 10.2, 10.3 and 10.4, respectively, to this Current Report on Form 8-K and is incorporated by reference herein.

---

| | |
|:---|:---|
| **Item 3.02** | **Unregistered Sales of Equity Securities** |

---

On December 30, 2025, the Company issued an aggregate of 4,600,000 shares of Common Stock in private, unregistered transactions, including (i) 900,000 shares to Baker Bros. pursuant to the Baker Settlement, (ii) 2,200,000 shares to LifeSci pursuant to the LifeSci Settlement, and (iii) 1,100,000 shares to Delaware IR pursuant to the Delaware IR Settlement. The remaining 400,000 shares of Common Stock were issued to employees. The Company issued the shares in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure** |

---

On January 5, 2026, the Company issued a press release regarding (i) the payment of $2 million to Oxford Finance, LLC as described in the Company's Current Report on Form 8-K filed on January 2, 2026 and (ii) the issuance of the 400,000 shares of Common Stock to employees described in this Current Report.

The information in this Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Settlement Agreement and Mutual Release, dated December 30, 2025, by and between KALA BIO Inc. and Baker Bros. Advisors LP.](kalabio_ex10-1.htm) |
| 10.2 | [Voting Agreement, dated December 30, 2025, by and between KALA BIO Inc. and Baker Bros. Advisors LP.](kalabio_ex10-2.htm) |
| 10.3 | [Settlement Agreement and Mutual Release, dated December 30, 2025, by and between KALA BIO Inc. and LifeSci Capital LLC.](kalabio_ex10-3.htm) |
| 10.4 | [Settlement Agreement, dated December 30, 2025, by and between KALA BIO Inc. and Delaware IR LLC.](kalabio_ex10-4.htm) |
| 99.1 | [Press Release, dated January 5, 2026](kalabio_ex99-1.htm) |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | KALA BIO, INC. | KALA BIO, INC. |
| Date: January 6, 2026 | By: | */s/ David Lazar* |
|  |  | David Lazar |
|  |  | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**<u>SETTLEMENT AGREEMENT AND MUTUAL RELEASE</u>**

This Settlement Agreement and General and Mutual Release (the "Settlement") is on this 30<sup>th</sup> day of December (the "Effective Date") by and between KALA BIO Inc. (the "Company") and Baker Bros. Advisors LP (the "Provider"), collectively known herein as the "Parties."

**WHEREAS,** the Provider had certain participation rights under Section 6.06(a) of the securities purchase agreement dated November 28, 2022, related to funding for the Company., pursuant to a securities purchase agreement with David Lazar dated November 23, 2025 (the "Rights").

**WHEREAS,** there was additional funding for the Company where the Rights were not exercised.

**WHEREAS,** the Parties desire and intend that this Settlement supplement all prior contracts, agreements and understandings between the Parties.

**WHEREAS,** the Parties desire and intend to fully, completely and finally resolve and terminate all claims and actions arising or related in any way to the Company's responsibility for payment to Provider regarding the Rights.

**NOW, THEREFORE**, the Parties, intending to be legally bound, and in consideration of the mutual promises, covenants and agreements contained herein and other good and valuable consideration, the sufficiency of which is hereby acknowledged, agree as follows:

1. <u>Settlement Payments Due to the Provider from the Company</u>. The Company shall issue to the Provider 900,000 shares of the Company's common stock (the "Equity Settlement"), on or prior to December 30, 2025.

2. <u>Releases</u>.

a. The Provider, for itself, its principals and for any successors and assigns hereby irrevocably and unconditionally releases, acquits and forever discharges the Company and any principals of any and any successors and assigns (and any officers, directors, shareholders, managers, members, employees, representatives, attorneys, consultants, and agents of such entities) (hereinafter referred to for purposes of this section as the "Clients"), from any and all claims, demands, rights, causes of action, liens, actions, suits, attorneys' fees, costs, damages, losses, expenses and contractual obligations of whatever kind or nature, whether absolute or contingent, liquidated or unliquidated, direct or indirect, in law or in equity, fully accrued or not fully accrued, matured or unmatured, known or unknown, foreseen or unforeseen, suspected or unsuspected, arising out of the Agreement insofar as they relate to the Rights rendered by Provider to Company prior to the effective date hereof (collectively, "Claims"), which the Provider had, currently has, shall or may have. Notwithstanding the foregoing, the release contained herein shall not release Provider from their obligations pursuant to this Settlement.

b. The
 Company, for itself and for its successors and assigns hereby irrevocably and unconditionally release, acquit and forever discharge
 the Provider, any successors and assigns (and any officers, directors, shareholders, managers, members, employees, representatives, attorneys, consultants, and agents of such entities), from any and all Claims (as defined above) which the Company had,
currently has, shall or may have. Notwithstanding the foregoing, the release contained herein shall not release Company from their obligations
pursuant to this Settlement.

3. <u>No Admission</u>. The Parties understand and agree that this Settlement shall not be construed as an admission of liability by one party to the other or that either party has violated any federal, state or local statute, law, ordinance or regulation.

4. <u>Binding Agreement</u>. This Settlement supersedes all prior agreements between the Parties. This Settlement shall be binding upon the Parties hereto and their respective successors and assigns. The Parties agree and stipulate that this Settlement is enforceable in all respects and is not subject to any affirmative claim, once this Settlement is executed.

5. <u>Entire Agreement</u>. This Settlement constitutes the entire and complete understanding between the Parties related to the subject matter hereof, and no other representation, promise, or agreement shall be binding upon either of them unless it is in writing and executed by the Parties. The operational activities between the Parties under any work orders, proposals, and the like, including any terminations thereof and directions to dispose of Company materials, remain unchanged hereby.

6. <u>Amendment</u>. This Settlement may not be amended or modified in any manner except by a writing signed by each of the Parties hereto.

7. <u>Recitals</u>. The Parties hereto acknowledge and agree that the recitals set forth at the beginning of this Settlement are true and correct in all respects and are incorporated herein by this reference.

8. <u>Governing Law; Venue</u>. This Settlement is made and delivered in and shall be governed by and construed in accordance with, the applicable laws of the State of New York. Any suit involving any dispute or matter arising under this Settlement, the Parties hereby consent to personal jurisdiction in the State of New York and the Parties hereby agree that the exclusive venue shall be New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York (or any appellate courts thereof).

9. <u>Severability</u>. If any provision of this Settlement is held to be illegal, invalid or unenforceable, the provision shall be modified to the extent necessary to render it enforceable and, if necessary, shall be fully severable.

10. <u>Authority</u>. Each signer below warrants that he/she has actual authority to enter into this Agreement. It is understood that each party to this Settlement is relying on the other party executing this Settlement having actual authority to enter into the Settlement.

11. <u>Counterparts</u>. This Settlement may be executed in one or more counterparts, all of which shall be considered one and the same Agreement and each of which shall be deemed an original. An executed counterpart of this Settlement faxed or scanned and emailed shall have the same force and effect as an originally executed counterpart.

12. <u>Waiver of Jury Trial</u>. EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS SETTLEMENT.

13. <u>Encouragement to Consult Attorney; Time to Consider Agreement</u>. EACH OF PARTIES REPRESENTS THAT THIS SETTLEMENT HAS BEEN ENTERED INTO FREELY AND VOLUNTARILY; THAT IT HAS HAD THE OPPORTUNITY TO ASCERTAIN AND WEIGH ALL OF THE FACTS AND CIRCUMSTANCES LIKELY TO INFLUENCE ITS JUDG- MENTS; THAT IT HAS HAD THE OPPORTUNITY TO SEEK AND OBTAIN LEGAL COUNSEL, AND HAS AVAILED ITSELF OF COUNSEL PRIOR TO SIGNING THIS SETTLEMENT, AND TO BE DULY APPRISED OF ITS LEGAL RIGHTS; AND THAT IT HAS READ AND FULLY UNDERSTANDS THE TERMS OF THE SETTLEMENT.

14. <u>Non-Disparagement</u>. The Parties agrees that they will not say, write or cause to be said or written, any statement that may be considered defamatory, derogatory or disparaging of any of the other Parties.

15. <u>Conditional Nature of Settlement</u>. The Company's representatives or agents have represented to Provider that that this Settlement is being entered into as a necessary part of an attempt by Company to find investors to acquire its assets rather than Company entering into bankruptcy, and Provider is willing to accept the lower amount than it is owed in order to recoup more payment than it is likely to receive as an unsecured creditor or Company. In the event Company is unsuccessful and Company enters into receivership or bankruptcy, this Settlement is likely to be invalidated and the payment above may be clawed back by the bankruptcy trustee, yet Provider may be barred from further recovery by the above release and waiver. Accordingly, the Parties agree that if Company enters into bankruptcy or similar proceedings within five (5) years of executing this Settlement, Provider's waiver of claims is automatically rescinded and Provider shall have the right to seek compensation for the full amount it is owed by Company as of the Effective Date

16. <u>Voting Agreement</u>. The Parties shall enter into a mutually agreed upon voting agreement on even date hereof.

17. <u>Piggy-Back Registration Rights</u>. All shares of common stock issued by the Company to the Provider pursuant to any of Section 1 above shall also grant the Provider with the right to include any and all such shares on each new registration statement that the Company files with SEC following the date hereof, subject to pro rata reductions of the shares being registered pursuant to comments of the staff of the SEC (the "Registration Rights"). The Registration Rights (i) are not applicable to any prospectus supplements to existing registration statements and (ii) shall transfer with the applicable shares when and if such shares are transferred by the Provider.

IN WITNESS WHEREOF, the Parties have made and entered into this Settlement Agreement And Mutual Release as of the Effective Date.

---

| | |
|:---|:---|
| **KALA BIO Inc.** | **KALA BIO Inc.** |
| /s/ David Lazar | /s/ David Lazar |
| By: | David Lazar |
| Its: | Chief Executive Officer |

---

---

| | |
|:---|:---|
| **Baker Bros. Advisors LP** | **Baker Bros. Advisors LP** |
| /s/ Scott Lessing | /s/ Scott Lessing |
| By: | Scott Lessing |
| Its: | President |

---

## Exhibit 10.2

**Exhibit 10.2**

**VOTING AGREEMENT**

THIS VOTING AGREEMENT (this "**Agreement**") is being signed on December 30, 2025 (the "**Signature Date**") by and between Kala Bio, Inc. a Delaware corporation whose Common Stock is listed for trading on the Nasdaq (the "**Proxy**" or the "**Company**"), and Baker Bros. Advisors LP, and any affiliates thereof (the "**Stockholder**").

WHEREAS, the Company and the Stockholder are contemplating entering into a Settlement Agreement and Mutual Release (the "**Settlement Agreement**") that will provide for the issuance of, *inter alia,* shares of the Company's common stock, par value $0.01 per share ("**Common Stock**"), subject to and in accordance with the terms of the Settlement Agreement once finalized, and in connection with that Settlement Agreement, the Stockholder desires to provide the Proxy with certain contractual rights as set forth below.

NOW, THEREFORE, in consideration of the recitals set forth hereinabove and the mutual covenants and agreements herein contained, and other good and valuable consideration, the receipt and sufficiency of which are acknowledged hereby, each of the parties hereto, intending legally to be bound, hereby agrees as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1. <u>Incorporation of Recitals</u>.** The parties to this Agreement hereby agree and acknowledge that all of the Recitals set forth hereinabove are true, complete and correct in every respect and hereby incorporate said Recitals into this Agreement by this reference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2. <u>Representations of the Stockholder</u>**. The Stockholder hereby represents and warrants to the Proxy that it: (a) has full power to enter into this Agreement and has not, prior to the Signature Date, executed and/or delivered any proxy or entered into any other voting agreement or similar arrangement and (b) will not take any action inconsistent with the purposes and provisions of this Agreement. Without limiting the above or anything otherwise in this Agreement, the Stockholder represents that neither it nor, any of its representatives or affiliates has (i) entered into (and, except with the prior written consent of the Proxy, agrees that it will not and will use reasonable efforts to ensure that its representatives and affiliates will not enter into) directly or indirectly, any agreement, arrangement or understanding with any person or firm as a principal, co-investor or co-bidder with respect to a possible transaction involving the Company or that would restrict the ability of any other person to provide debt, equity or other financing for a possible transaction involving the Company or (ii) engaged in any discussions which might lead to any agreement, arrangement or understanding with any such person or firm.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3. <u>Escrow of Agreement</u>**. Upon execution of this Agreement, it shall be placed in escrow with ABZ Law, until the complete execution and effectiveness of the Settlement Agreement by the Company and the Stockholder, at which time this Agreement shall be released from such escrow to the benefit of the Proxy (the "**Proxy Effective Date**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4. <u>Scope of Agreement</u>.** Upon and following the Proxy Effective Date, this Agreement pertains to the vote of the 900,000 shares of Common Stock (the "**Issued Shares**"), representing the aggregate voting interest of the Stockholder immediately following the Signature Date, as well as any additional shares of Common Stock which are held by the Stockholder on December 30, 2025 (together with the Issued Shares, the "**Proxy Shares**") by the Proxy with respect to any and all matters concerning a stockholder vote in respect of the Proxy Shares with respect to actions to be taken by the Company and <u>recommended by</u> the Board of Directors of the Company at the upcoming special or annual meeting of stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5. <u>Changes in Capital Stock</u>**. In the event that subsequent to the Signature Date, any shares of capital stock or other securities the Company are issued on, or in exchange for, any of the Issued Shares by reason of any stock dividend, stock split, consolidation of shares, reclassification, exchange, merger or consolidation or otherwise involving the Company, such shares of capital stock or other securities shall be deemed to be Proxy Shares for purposes of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6. <u>Voting of Proxy Shares</u>.** The Stockholder agrees and covenants that at any meeting of the stockholders of the Company and/or in connection with any corporate action by the stockholders of the Company from the Signature Date until the termination of this Agreement, all of his/its respective Issued Shares and the Proxy Shares shall be voted by the Stockholder in favor of all proposals recommended by the Board of Directors of the Company that are presented for stockholder approval as set forth in Section 4 above or otherwise. The Stockholder agrees to promptly vote their Proxy Shares within seven (7) days after the Company files a definitive proxy statement for a meeting of its stockholders, if applicable. To the extent that such shares are not voted, then the Stockholder grants the Company an irrevocable proxy, as provided in Section 7, to vote all of the Proxy Shares in the manner and to the effect determined by said Proxy in his sole and absolute discretion with respect to actions proposed to be taken by the Company. Accordingly, during the term of this Agreement, no Stockholder shall vote or attempt to vote any of his/its respective shares of the Proxy Shares, or otherwise exercise or attempt to exercise any voting or other approval rights of any of his/its respective shares of the Proxy Shares except as provided in this Section 6, and any such prohibited exercise by any Stockholder of voting or approval rights shall be void and of no force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7. <u>Irrevocable Proxy</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) In order to give effect to and in furtherance of the agreements and covenants set forth in this Agreement, the Stockholder hereby irrevocably constitutes and appoints Proxy as proxy for such Stockholder, with full power of substitution, for and in the name and on behalf of such Stockholder, to vote any and all of his/its respective shares of Proxy Shares with regard to any question, action, resolution, election or other matter presented to the stockholders of the Company in favor of and/or approval with respect to actions proposed to be taken by the Company. Proxy shall vote said Proxy Shares in such manner and to such effect as the Proxy may determine in his sole and absolute discretion with respect to actions proposed to be taken. The proxy granted hereby shall remain in effect for so long as and at all times that this Agreement shall remain in effect. The proxy granted hereby is irrevocable and is coupled with an interest sufficient in law to support an irrevocable proxy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Proxy hereby accepts its appointment as proxy of the Stockholder, pursuant to Subsection 7(a) of this Agreement. Other than as specifically set forth herein, the Proxy shall have no other rights with respect to the Proxy Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) In no way shall the terms of this Agreement be interpreted in a way to cause a violation of Section 160(c) of the Delaware General Corporate Law or to prohibit, limit or restrict Proxy from exercising any fiduciary duties as an officer and/or director to the Company at and from such time as the Proxy may be such.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The voting of Proxy Shares pursuant to this Agreement may be effected in person, by proxy, by written consent or in any other manner permitted by applicable law. For the avoidance of doubt, voting of the Proxy Shares pursuant to the Agreement need not make explicit reference to the terms of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8. <u>Limitation of Proxy's Liability</u>.** Proxy shall not incur any liability or responsibility by reason of any error of judgment, mistake of law or other mistake, or for any act or omission of any agent or attorney, or for any misconstruction of this Agreement, or for any action of any kind taken or omitted hereunder or believed by him to be in accordance with the provisions and intents hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9. <u>Consideration</u>.** In exchange for the Irrevocable Proxy and the transfer of the voting rights of the Stockholder, the Company shall use all commercially reasonable efforts to 1) execute the Settlement Agreement and undertake the actions contemplated therein and 2) cause the Issued Shares to be issued in accordance with the Settlement Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10. <u>Term</u>.** This Agreement, as it applies to the Issued Shares, shall commence on the Signature Date and expire upon the one (6) month anniversary of the Proxy Effective Date, unless earlier terminated by Proxy, in Proxy's sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11. <u>Successor Proxy</u>**. In the event that the Proxy is unable or unwilling to serve as the Proxy, a successor proxy (who will become the Proxy under this Agreement, if appointed in accordance with this Section 11) may be appointed by the Proxy at its discretion, or if the Proxy is unable to make such appointment by the consent of the successors to the Company's individual shares of capital stock that hold a majority interest in such shares. A successor proxy shall be vested with all the rights, powers and authority as if originally named in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12. Intentionally Omitted.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13. <u>Governing Law; Jurisdiction and Venue</u>.** This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to rules regarding choice of law. **EACH PARTY HERETO AGREES TO SUBMIT TO THE PERSONAL JURISDICTION AND VENUE OF THE STATE AND/OR FEDERAL COURTS LOCATED IN WILMINGTON, DELAWARE FOR RESOLUTION OF ALL DISPUTES ARISING OUT OF, IN CONNECTION WITH, OR BY REASON OF THE INTERPRETATION, CONSTRUCTION, AND ENFORCEMENT OF THIS AGREEMENT AND/OR ANY ADOPTION AGREEMENT, AND HEREBY WAIVES THE CLAIM OR DEFENSE THEREIN THAT SUCH COURTS CONSTITUTE AN INCONVENIENT FORUM.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**14. <u>Benefits; Binding Effect</u>.** This Agreement shall be for the benefit of and binding upon the parties hereto and their respective heirs, personal representatives, legal representatives, successors, assigns and transferees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**15. <u>Counterparts</u>.** This Agreement may be executed in several counterparts, and all so executed shall constitute one Agreement, binding on all the parties hereto, notwithstanding that all the parties are not signatories to the original or same counterpart.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**16. <u>Amendment or Modification</u>.** This Agreement may be altered, modified or amended only by the unanimous consent, in writing, of the parties hereto, either now or hereafter. Any such modification must be signed by each party to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**17. <u>Titles and Subtitles</u>**. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**18. <u>Notices</u>**. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient's next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their address as set forth on <u>Schedule A</u> hereto, or to such email address or address as subsequently modified by written notice given in accordance with this Section 18.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**19. <u>Delays or Omissions</u>**. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default previously or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**20. <u>Further Assurances</u>**. At any time or from time to time after the date hereof, the parties agree to cooperate with each other, and at the request of any other party, to execute and deliver any further instruments or documents and to take all such further action as the other party may reasonably request in order to evidence or effectuate the consummation of the transactions contemplated hereby and to otherwise carry out the intent of the parties hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**21. <u>Specific Enforcement</u>**. The Stockholder acknowledges and agrees that irreparable harm will result in the event any of the provisions of this Agreement are not performed by the Stockholder in accordance with their specific terms or are otherwise breached. Accordingly, it is agreed that the Company shall be entitled to an injunction to prevent breaches of this Agreement, and to specific enforcement of this Agreement and its terms and provisions in any action instituted in any court of the United States or any state having subject matter jurisdiction, as further provided in Section 23.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**22. <u>Entire Agreement</u>.** This Agreement constitutes the entire agreement among the parties hereto with respect to the subject matter hereof and supersedes all prior agreements, understandings and arrangements, both oral and written, among the parties hereto with respect to such subject matter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**23. <u>Enforceability</u>**. The parties expressly agree that this Agreement shall be specifically enforceable in any court of competent jurisdiction in the United States in accordance with its terms against each of the parties hereto. If any provision of this Agreement shall be declared void or unenforceable by any court or administrative board of competent jurisdiction, such provision shall be deemed to have been severed from the remainder of this Agreement and this Agreement shall continue in all respects to be valid and enforceable and shall be construed so as to best give effect to the intention of the voided or unenforceable term or provision.

[*Signature Page Follows*]

**IN WITNESS WHEREOF**, the parties have executed this Voting Agreement as of the Signature Date.

---

| | |
|:---|:---|
| KALA BIO, INC. | KALA BIO, INC. |
| By: | /s/ David Lazar |
| BAKER BROS. ADVISORS LP | BAKER BROS. ADVISORS LP |
| By: | /s/ Scott Lessing |

---

**<u>Schedule A</u>**

---

| | |
|:---|:---|
| **Company/Proxy:** | Kala Bio, Inc. |
|  | Address: 1167 Massachusetts Avenue, Arlington, MA 02476 |
|  | Attention: |
|  | E-mail: |
|  | With a copy, which shall not constitute notice, shall also be sent to |
| **Stockholder:** | Baker Bros. Advisors LP |
|  | Address: 860 Washington Street, Floor 3, New York, NY 10014 |
|  | Attention: |
|  | E-mail: |

---

## Exhibit 10.3

**Exhibit 10.3**

&nbsp;&nbsp;&nbsp;&nbsp;**<u>SETTLEMENT AGREEMENT AND MUTUAL RELEASE</u>**

This Settlement Agreement and General and Mutual Release (the "Settlement") is on this 30<sup>th</sup> day of December (the "Effective Date") by and between KALA BIO Inc. (the "Company") and LifeSci Capital LLC (the "Provider"), collectively known herein as the "Parties."

**WHEREAS,** the Provider was engaged by the Company to perform certain financial advisory services to the Company with respect to the Company's efforts to engage in a transaction (or series of related transactions) pursuant to which the Company (i) effectuates a merger, acquisition, or other business combination or similar acquisition transaction and/or (ii) offers securities to raise capital in connection with a financing transaction (the "Services") in accordance with an engagement agreement between Provider and Company, dated November 2, 2025 (the "Agreement").

**WHEREAS,** the Provider provided the Services to Company.

**WHEREAS,** the Parties desire and intend that this Settlement supplement and modify all prior contracts, agreements and understandings between the Parties.

**WHEREAS,** the Parties desire and intend to fully, completely and finally resolve and terminate all claims and actions arising or related in any way to the Company's responsibility for payment to Provider for the Services.

**NOW, THEREFORE**, the Parties, intending to be legally bound, and in consideration of the mutual promises, covenants and agreements contained herein and other good and valuable consideration, the sufficiency of which is hereby acknowledged, agree as follows:

1. <u>Settlement Payments Due to the Provider from the Company</u>. The Company shall issue to the Provider 2,200,000 shares of the Company's common stock (the "Equity Settlement"), on December 30, 2025. This Equity Settlement is separate from the $420,000 cash private placement fee already agreed upon between the Company and the Provider for the offering announced by the Company on December 1, 2025.

2. <u>Releases</u>.

a. The Provider, for itself, its principals and for any successors and assigns hereby irrevocably and unconditionally releases, acquits and forever discharges the Company and any principals of any and any successors and assigns (and any officers, directors, shareholders, managers, members, employees, representatives, attorneys, consultants, and agents of such entities) (hereinafter referred to for purposes of this section as the "Clients"), from any and all claims, demands, rights, causes of action, liens, actions, suits, attorneys' fees, costs, damages, losses, expenses and contractual obligations of whatever kind or nature, whether absolute or contingent, liquidated or unliquidated, direct or indirect, in law or in equity, fully accrued or not fully accrued, matured or unmatured, known or unknown, foreseen or unforeseen, suspected or unsuspected, arising out of the Agreement insofar as they relate to payment for services rendered by Provider to Company prior to the effective date hereof (collectively, "Claims"), which the Provider had, currently has, shall or may have. Notwithstanding the foregoing, the release contained herein shall not release Provider from their obligations pursuant to this Settlement.

b. The Company, for itself and for its successors and assigns hereby irrevocably and unconditionally release, acquit and forever discharge the Provider, any successors and assigns (and any officers, directors, shareholders, managers, members, employees, representatives, attorneys, consultants, and agents of such entities), from any and all Claims (as defined above) which the Company had, currently has, shall or may have. Notwithstanding the foregoing, the release contained herein shall not release Company from their obligations pursuant to this Settlement.

3. <u>No Admission</u>. The Parties understand and agree that this Settlement shall not be construed as an admission of liability by one party to the other or that either party has violated any federal, state or local statute, law, ordinance or regulation.

4. <u>Binding Agreement</u>. This Settlement supersedes all prior agreements between the Parties. This Settlement shall be binding upon the Parties hereto and their respective successors and assigns. The Parties agree and stipulate that this Settlement is enforceable in all respects and is not subject to any affirmative claim, once this Settlement is executed.

5. <u>Entire Agreement</u>. This Settlement constitutes the entire and complete understanding between the Parties related to the subject matter hereof, and no other representation, promise, or agreement shall be binding upon either of them unless it is in writing and executed by the Parties. The operational activities between the Parties under any work orders, proposals, and the like, including any terminations thereof and directions to dispose of Company materials, remain unchanged hereby.

6. <u>Amendment</u>. This Settlement may not be amended or modified in any manner except by a writing signed by each of the Parties hereto.

7. <u>Recitals</u>. The Parties hereto acknowledge and agree that the recitals set forth at the beginning of this Settlement are true and correct in all respects and are incorporated herein by this reference.

8. <u>Governing Law; Venue</u>. This Settlement is made and delivered in, and shall be governed by and construed in accordance with, the applicable laws of the State of New York. Any suit involving any dispute or matter arising under this Settlement, the Parties hereby consent to personal jurisdiction in the State of New York and the Parties hereby agree that the exclusive venue shall be New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York (or any appellate courts thereof).

9. <u>Severability</u>. If any provision of this Settlement is held to be illegal, invalid or unenforceable, the provision shall be modified to the extent necessary to render it enforceable and, if necessary, shall be fully severable.

10. <u>Authority</u>. Each signer below warrants that he/she has actual authority to enter into this Agreement. It is understood that each party to this Settlement is relying on the other party executing this Settlement having actual authority to enter into the Settlement.

11. <u>Counterparts</u>. This Settlement may be executed in one or more counterparts, all of which shall be considered one and the same Agreement and each of which shall be deemed an original. An executed counterpart of this Settlement faxed or scanned and emailed shall have the same force and effect as an originally executed counterpart.

12. <u>Waiver of Jury Trial</u>. EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS SETTLEMENT.

13. <u>Encouragement to Consult Attorney; Time to Consider Agreement</u>. EACH OF PARTIES REPRESENTS THAT THIS SETTLEMENT HAS BEEN ENTERED INTO FREELY AND VOLUNTARILY; THAT IT HAS HAD THE OPPORTUNITY TO ASCERTAIN AND WEIGH ALL OF THE FACTS AND CIRCUMSTANCES LIKELY TO INFLUENCE ITS JUDG- MENTS; THAT IT HAS HAD THE OPPORTUNITY TO SEEK AND OBTAIN LEGAL COUNSEL, AND HAS AVAILED ITSELF OF COUNSEL PRIOR TO SIGNING THIS SETTLEMENT, AND TO BE DULY APPRISED OF ITS LEGAL RIGHTS; AND THAT IT HAS READ AND FULLY UNDERSTANDS THE TERMS OF THE SETTLEMENT.

14. <u>Non-Disparagement</u>. The Parties agrees that they will not say, write or cause to be said or written, any statement that may be considered defamatory, derogatory or disparaging of any of the other Parties.

15. <u>Conditional Nature of Settlement</u>. The Company's representatives or agents have represented to Provider that that this Settlement is being entered into as a necessary part of an attempt by Company to find investors to acquire its assets rather than Company entering into bankruptcy, and Provider is willing to accept the lower amount than it is owed in order to recoup more payment than it is likely to receive as an unsecured creditor or Company. In the event Company is unsuccessful and Company enters into receivership or bankruptcy, this Settlement is likely to be invalidated and the payment above may be clawed back by the bankruptcy trustee, yet Provider may be barred from further recovery by the above release and waiver. Accordingly, the Parties agree that if Company enters into bankruptcy or similar proceedings within five (5) years of executing this Settlement, Provider's waiver of claims is automatically rescinded and Provider shall have the right to seek compensation for the full amount it is owed by Company as of the Effective Date

16. <u>Voting Agreement</u>. The Parties shall enter into a mutually agreed upon voting agreement on even date hereof.

17. <u>Piggy-Back Registration Rights</u>. All shares of common stock issued by the Company to the Provider pursuant to any of Section 1 above shall also grant the Provider with the right to include any and all such shares on each new registration statement that the Company files with SEC following the date hereof, subject to pro rata reductions of the shares being registered pursuant to comments of the staff of the SEC (the "Registration Rights"). The Registration Rights (i) are not applicable to any prospectus supplements to existing registration statements and (ii) shall transfer with the applicable shares when and if such shares are transferred by the Provider.

IN WITNESS WHEREOF, the Parties have made and entered into this Settlement Agreement And Mutual Release as of the Effective Date.

---

| | |
|:---|:---|
| **KALA BIO Inc.** | **KALA BIO Inc.** |
| /s/ David Lazar | /s/ David Lazar |
| By: | David Lazar |
| Its: | Chief Executive Officer |

---

---

| | |
|:---|:---|
| **LifeSci Capital LLC** | **LifeSci Capital LLC** |
| /s/ Andrew McDonald | /s/ Andrew McDonald |
| By: | Andrew McDonald |
| Its: | Chief Executive Officer |

---

## Exhibit 10.4

**Exhibit 10.4**

**DEBT SETTLEMENT AGREEMENT**

This **DEBT SETTLEMENT AGREEMENT** (this "**Agreement**") is made and entered into as of December 30, 2025, by and between:

Kala Bio, Inc. (the "**Company**") and Delaware IR LLC, with a principal place of business at 8, The Green STE A, Dover, Delaware 19901 (the "**Creditor**");

**WHEREAS** the Creditor is a creditor of the Company that is currently owed $600,000.00 (the "**Debt**") for invoices, disbursements, and applicable taxes;

**AND WHEREAS** the Company has agreed to issue to the Creditor and the Creditor has agreed to accept 1,100,000 common stock of the Company, par value $0.001 per share ("**Debt Settlement Shares**");

**NOW THEREFORE**, in consideration of the mutual covenants and promises contained herein, and for valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the parties to this Agreement (collectively "**parties**" and individually a "**party**") agree as follows:

1. The
 Company agrees to issue to the Creditor, and the Creditor agrees to accept, the Debt Settlement Shares as complete payment
 and settlement of the Debt, provided that upon selling the Debt Settlement Shares, the Creditor has received net proceeds
 from the sale of the Debt Settlement Shares ()"**Net Proceeds**") equal to the Debt. The Company and the Creditor
 agree that for any losses that the Creditor may suffer, if any, calculated as the Debt minus the Net Proceeds, shall be added
 to the Debt on a dollar- for-dollar basis by the amount of the loss.

2. The
 parties acknowledge and confirm the Debt Settlement Shares are being issued pursuant to the prospectus exemption *.* 

3. This
 Agreement may be executed either by original, electronic or facsimile signature and may be executed by the parties in one
 or more counterparts, each of which when so executed and delivered shall be an original and such counterparts shall together
 constitute one and the same instrument.

4. This
 Agreement shall in all respects be interpreted, enforced and governed under the laws of the State of New York, without regard
 to the principles of conflicts of law thereof.

5. This
 Agreement shall enure to the benefit of and shall be binding upon the undersigned and their respective successors and permitted
 assigns.

6. This
 Agreement memorializes and constitutes the entire agreement and understanding among the parties regarding the subject matter
 hereof, and supersedes all prior negotiations, proposed agreements and agreements, whether written or unwritten. The parties
 acknowledge that no other party, nor any agent or attorney of any other party, has made any promises, representations, or
 warranties whatsoever, expressly or impliedly, which are not expressly contained in this Agreement, and the parties further
 acknowledge that they have not executed this Agreement in reliance upon any collateral promise, representation, warranty,
 or in reliance upon any belief as to any fact or matter not expressly recited in this Agreement.

[*Signature page follows*]

**IN WITNESS WHEREOF,** the parties hereto enter into this Agreement as of the date first above written.

---

| | | | |
|:---|:---|:---|:---|
| **KALA BIO, INC.** | **KALA BIO, INC.** | **DELAWARE IR LLC** | **DELAWARE IR LLC** |
| By: | /s/ David Lazar | By: | /s/ Menachem Wagner |
| Name: | David Lazar | Name: | Menachem Wagner |
| Title: | Chairman and CEO | Title: | Manager |
| I have authority to bind the corporation. | I have authority to bind the corporation. | I have authority to bind the corporation. | I have authority to bind the corporation. |

---

## Exhibit 99.1

**Exhibit 99.1**

**KALA BIO Settles Approximately $10.6 million of Debt**

**ARLINGTON, Mass., January 5, 2026** – KALA BIO, Inc. (NASDAQ:KALA), ("KALA" or the "Company") today announced the successful completion of its loan settlement with Oxford Finance, LLC ("Oxford"), marking a transformational milestone for the Company. The completion of the settlement resolves critical debt obligations.

As previously disclosed in the Company's Current Report on Form 8-K filed on November 25, 2025, KALA and its subsidiary Combangio, Inc., entered into a Loan Settlement Agreement with Oxford pursuant to which the Company owed Oxford $2 million to be paid pursuant to the terms of the Settlement Agreement. The Settlement Agreement was negotiated in connection with events of default under the Loan and Security Agreement dated May 4, 2021 (the "Loan Agreement").

Recently, KALA completed its $2 million payment obligation to Oxford. Effective immediately upon this payment, the Company is pleased to announce that it has settled the Oxford debt obligations of approximately $10.6 million as of December 26, 2025. As a direct result of this $2 million payment, all of the Company's obligations under both the Settlement Agreement and the underlying Loan Agreement have been fully satisfied and discharged.

"The successful completion of the Oxford settlement represents a watershed moment for KALA BIO," said David E. Lazar, Chief Executive Officer and Chairman of the Board. "By settling the Company's debt obligations and increasing stockholders' equity, we have removed a substantial overhang that was constraining the Company's strategic flexibility. We are confident in our path forward."

Also, as of December 30, 2025, the Company, with the Compensation Committee of KALA's Board of Directors' approval, granted common stock awards as a material inducement to employment to four individuals hired by KALA, which common stock awards relate to, in the aggregate, 400,000 shares of common stock.